MA52200A - Compositions de vaa, procédés de préparation et méthodes d'utilisation - Google Patents

Compositions de vaa, procédés de préparation et méthodes d'utilisation

Info

Publication number
MA52200A
MA52200A MA052200A MA52200A MA52200A MA 52200 A MA52200 A MA 52200A MA 052200 A MA052200 A MA 052200A MA 52200 A MA52200 A MA 52200A MA 52200 A MA52200 A MA 52200A
Authority
MA
Morocco
Prior art keywords
methods
preparation
aav compositions
aav
compositions
Prior art date
Application number
MA052200A
Other languages
English (en)
Inventor
Valerie Girard
Tuyen Ong
Richard Truran
Original Assignee
Nightstarx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nightstarx Ltd filed Critical Nightstarx Ltd
Publication of MA52200A publication Critical patent/MA52200A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091Purification or manufacturing processes for gene therapy compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/0031Serum-free culture media
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/005Protein-free medium
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y205/00Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/0106Protein geranylgeranyltransferase type II (2.5.1.60)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/42Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/48Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/50Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1085Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Manufacturing & Machinery (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA052200A 2018-04-05 2019-04-05 Compositions de vaa, procédés de préparation et méthodes d'utilisation MA52200A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862653139P 2018-04-05 2018-04-05
US201862746980P 2018-10-17 2018-10-17
US201862773975P 2018-11-30 2018-11-30

Publications (1)

Publication Number Publication Date
MA52200A true MA52200A (fr) 2021-02-17

Family

ID=66223873

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052200A MA52200A (fr) 2018-04-05 2019-04-05 Compositions de vaa, procédés de préparation et méthodes d'utilisation

Country Status (19)

Country Link
US (1) US20210145929A1 (fr)
EP (1) EP3775234A1 (fr)
JP (1) JP2021520233A (fr)
KR (1) KR20210005045A (fr)
CN (1) CN112384626A (fr)
AU (1) AU2019247866A1 (fr)
BR (1) BR112020020174A2 (fr)
CA (1) CA3096051A1 (fr)
CL (1) CL2020002566A1 (fr)
CO (1) CO2020013699A2 (fr)
CR (1) CR20200507A (fr)
IL (1) IL277786A (fr)
JO (1) JOP20200250A1 (fr)
MA (1) MA52200A (fr)
MX (1) MX2020010191A (fr)
PH (1) PH12020551642A1 (fr)
SG (1) SG11202009698PA (fr)
TW (1) TW202000905A (fr)
WO (1) WO2019195729A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023520149A (ja) * 2020-03-16 2023-05-16 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 組換えアデノ随伴ウイルス収量を増強させるための方法
WO2022051294A1 (fr) * 2020-09-02 2022-03-10 4D Molecular Therapeutics Inc. Gènes rep1 à codon optimisé et leurs utilisations
WO2022109247A1 (fr) * 2020-11-20 2022-05-27 Biogen Ma Inc. Test de puissance de vecteurs viraux
WO2023165969A1 (fr) 2022-03-03 2023-09-07 Evonik Operations Gmbh Procédé pour améliorer la production de vecteurs viraux dans une culture cellulaire à l'aide de glycyl-glutamine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2787827C (fr) * 2010-01-28 2020-11-10 The Children's Hospital Of Philadelphia Plateforme de fabrication evolutive pour purification de vecteurs viraux et vecteurs viraux ainsi purifies utilisables en therapie genique
GB201103062D0 (en) * 2011-02-22 2011-04-06 Isis Innovation Method
EP3054007A1 (fr) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Purification de particules de virus adéno-associés de recombinaison comprenant une étape de purification par affinité immunologique

Also Published As

Publication number Publication date
TW202000905A (zh) 2020-01-01
IL277786A (en) 2020-11-30
CO2020013699A2 (es) 2021-04-08
US20210145929A1 (en) 2021-05-20
CL2020002566A1 (es) 2021-04-16
JP2021520233A (ja) 2021-08-19
SG11202009698PA (en) 2020-10-29
CR20200507A (es) 2021-03-02
KR20210005045A (ko) 2021-01-13
WO2019195729A1 (fr) 2019-10-10
MX2020010191A (es) 2021-02-26
EP3775234A1 (fr) 2021-02-17
AU2019247866A1 (en) 2020-10-22
JOP20200250A1 (ar) 2020-10-04
CN112384626A (zh) 2021-02-19
PH12020551642A1 (en) 2021-07-26
BR112020020174A2 (pt) 2021-01-19
CA3096051A1 (fr) 2019-10-10

Similar Documents

Publication Publication Date Title
MA52200A (fr) Compositions de vaa, procédés de préparation et méthodes d'utilisation
MA54952A (fr) Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
MA45996A (fr) Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
MA49403A (fr) Compositions de pde5 et méthodes d'immunothérapie
MA50045A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA52492A (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
IL278013B1 (en) Modulators of secondary methyl enzymes, preparations and uses thereof
MA56032A (fr) Composés, compositions et procédés d'utilisation
MA50041A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA43811A (fr) Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
MX2019013151A (es) Composiciones y metodos para expresar otoferlina.
MA51430A (fr) Compositions de paire de bases non naturelles et procédés d'utilisation
MA45987A (fr) Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation
MA41988A (fr) Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa
MA44611A (fr) Compositions de composés hydrophobes cristallisés et leurs procédés de préparation et d'utilisation
MA55532A (fr) Composés de neuréguline-4 et procédés d'utilisation
MA53021A (fr) Composition de diacide oligosaccharidique d'alginate
MA44862A (fr) Formulations de fulvestrant et méthodes d'utilisation de celles-ci
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
EA202090193A1 (ru) Кристаллическая форма n-[1-(5-цианопиридин-2-илметил)-1h-пиразол-3-ил]-2-[4-(1-трифторметилциклопропил)фенил]ацетамида
MA51307A (fr) Compositions laitières fermentées et procédés de préparation de celles-ci
MA54085A (fr) Signatures d'interféron de type i et méthodes d'utilisation
MA52951A (fr) Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci